Candel Therapeutics, Inc. (CADL) Stock

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is led by CEO Paul-Peter Tak, employs 38 people, headquartered in US, publicly traded since 2021.

Candel Therapeutics, Inc. (CADL) stock trades at $8.03 with a market capitalization of $614.44M. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.22, reflecting a net loss over the last twelve months, price-to-book of 5.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.35 and $14.00, and currently trades 42.6% below its 52-week high.

On profitability, Candel Therapeutics, Inc. generates a return on equity (ROE) of -89.38% (negative, reflecting a net loss), return on capital employed of -36.83%.

Candel Therapeutics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Candel Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-38.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-88.0M.

Borrowings stand at $2.0M, cash from operations was $-38.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -108.9% over five years, and was -73.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Candel Therapeutics, Inc. (CADL) — frequently asked questions